Methods of treatment of endobronchial infections

Details for Australian Patent Application No. 2005258078 (hide)

Owner Novartis AG Novartis Vaccines and Diagnostics Inc.

Inventors Tarara, Thomas E.; Samara, Emil; Rodriguez, Carlos; Lord, John D.; Challoner, Peter

Agent FB Rice

Pub. Number AU-B-2005258078

PCT Pub. Number WO2006/002178

Priority 60/580,848 18.06.04 US

Filing date 20 June 2005

Wipo publication date 5 January 2006

Acceptance publication date 30 September 2010

International Classifications

A61K 9/12 (2006.01) Medicinal preparations characterised by special physical form - Aerosols

A61K 31/70 (2006.01) - Carbohydrates

A61K 47/36 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Polysaccharides

Event Publications

18 January 2007 PCT application entered the National Phase

  PCT publication WO2006/002178 Priority application(s): WO2006/002178

12 July 2007 Amendment Made

  The nature of the amendment is: Add co-inventor Samara, Emil

10 December 2009 Assignment before Grant

  Novartis Vaccines and Diagnostics Inc.; Nektar Therapeutics The application has been assigned to Novartis AG; Novartis Vaccines and Diagnostics Inc. Assignments before Grant, Section 113

30 September 2010 Application Accepted

  Published as AU-B-2005258078

27 January 2011 Standard Patent Sealed

4 August 2011 Assignment Registered

  Novartis AG; Novartis Vaccines and Diagnostics Inc. The patent has been assigned to Novartis AG

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005258080-Network content organization tool

2005258077-Interferon alpha receptor 1 antibodies and their uses